Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes
Treatment Failure With Hypomethylating Agents in Myelodysplastic Syndromes
TM Kadia, E Jabbour, H Kantarjian
Yes
20110901
2011 Oct 1
Semin Oncol
Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes
Semin Oncol. 2011 Oct 1;38(5):682-692, TM Kadia, E Jabbour, H Kantarjian
Abstract
Abstract
Hypomethylating agents such as 5-azacytidine or decitabine have been a major breakthrough in the treatment of patients with myelodysplastic syndromes (MDS). They have been shown to improve transfusion requirements and to change the natural history of the disease. However, with increasing cumulative clinical experience, it has become apparent that these agents are not curative and have their own shortcomings. There is a subgroup of patients who do not respond to frontline therapy and a large, growing...
